ENZC (Enzolytics) Total Receivables: $0.00 Mil (As of Jun. 2011)


What is Enzolytics Total Receivables?

Enzolytics ENZC -10.00% Total Receivables is $0.00 Mil as of Jun. 2011.

Enzolytics's Total Receivables for the quarter that ended in Jun. 2011 was $0.00 Mil.

Enzolytics Total Receivables Historical Data

* Premium members only.

The historical data trend for Enzolytics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Total Receivables Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Total Receivables
0.00 0.00 0.00 0.00

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.00 0.00

Enzolytics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Enzolytics (ENZC) has a Total Receivables of $0.00 Mil as of Jun. 2011. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Enzolytics and its competitors.
Is Enzolytics' Total Receivables too high?
Enzolytics' current Total Receivables is $0.00 Mil.
How does Enzolytics' Total Receivables compare to competitors?
Enzolytics' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Enzolytics and its competitors. Enzolytics's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Enzolytics (ENZC), the current Total Receivables is $0.00 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.